No Data
No Data
Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals
In the last three months, 8 analysts have published ratings on Catalyst Pharmaceuticals (NASDAQ:CPRX), offering a diverse range of perspectives from bullish to bearish.Summarizing their recent assessm
Catalyst Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Catalyst Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Catalyst Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 67.2% HC Wainwright & Co. $24 → $26 Maintains Buy 03/27/2024 86.5% Oppenheimer $29 → $29 Reiter
Express News | Catalyst Pharmaceuticals : H.c. Wainwright Raises Target Price to $26 From $24
HHS Panel to Vote in Nov. on DMD Screening for Newborns
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript